| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/27/2023 | 12.42% | Credit Suisse | → $101 | Reiterates | Neutral → Neutral |
| 07/06/2023 | 12.42% | Jefferies | $98 → $101 | Downgrades | Buy → Hold |
| 06/28/2023 | — | Benchmark | Downgrades | Buy → Hold | |
| 06/27/2023 | — | Benchmark | Downgrades | Buy → Hold | |
| 06/27/2023 | 12.42% | Truist Securities | $97 → $101 | Maintains | Hold |
| 06/07/2023 | 7.97% | Truist Securities | → $97 | Downgrades | Buy → Hold |
| 06/06/2023 | 11.31% | Cantor Fitzgerald | $91 → $100 | Maintains | Neutral |
| 06/06/2023 | 28.01% | Benchmark | → $115 | Reiterates | Buy → Buy |
| 06/06/2023 | 11.31% | Credit Suisse | $115 → $100 | Downgrades | Outperform → Neutral |
| 05/08/2023 | -6.5% | TD Cowen | $95 → $84 | Maintains | Market Perform |
| 05/05/2023 | -2.05% | Barclays | $93 → $88 | Maintains | Equal-Weight |
| 05/04/2023 | 7.97% | Truist Securities | $115 → $97 | Maintains | Buy |
| 05/04/2023 | 14.65% | Stephens & Co. | → $103 | Reiterates | → Equal-Weight |
| 04/21/2023 | -3.16% | Cantor Fitzgerald | → $87 | Initiates Coverage On | → Neutral |
| 04/13/2023 | 28.01% | Truist Securities | $130 → $115 | Maintains | Buy |
| 03/14/2023 | 28.01% | Benchmark | → $115 | Reiterates | → Buy |
| 03/14/2023 | 14.65% | Stephens & Co. | → $103 | Reiterates | → Equal-Weight |
| 03/13/2023 | 3.52% | Barclays | → $93 | Initiates Coverage On | → Equal-Weight |
| 02/27/2023 | 28.01% | Credit Suisse | → $115 | Reiterates | → Outperform |
| 02/21/2023 | 23.55% | RBC Capital | $114 → $111 | Maintains | Outperform |
| 02/16/2023 | 5.74% | Stephens & Co. | → $95 | Reiterates | → Equal-Weight |
| 02/16/2023 | 28.01% | Benchmark | $120 → $115 | Maintains | Buy |
| 02/13/2023 | 33.57% | Benchmark | → $120 | Reiterates | → Buy |
| 01/25/2023 | 33.57% | Benchmark | $135 → $120 | Maintains | Buy |
| 01/23/2023 | 28.01% | Credit Suisse | $140 → $115 | Maintains | Outperform |
| 01/19/2023 | 39.14% | Oppenheimer | $145 → $125 | Maintains | Outperform |
| 01/05/2023 | -5.39% | SVB Leerink | $96 → $85 | Maintains | Market Perform |
| 11/11/2022 | 17.99% | Stephens & Co. | $122 → $106 | Maintains | Equal-Weight |
| 11/01/2022 | 6.86% | SVB Leerink | $116 → $96 | Maintains | Market Perform |
| 11/01/2022 | 35.8% | Stephens & Co. | $105 → $122 | Maintains | Equal-Weight |
| 10/31/2022 | 54.72% | RBC Capital | $165 → $139 | Maintains | Outperform |
| 10/28/2022 | 40.25% | Barclays | $154 → $126 | Maintains | Overweight |
| 10/28/2022 | 16.87% | Stephens & Co. | $120 → $105 | Maintains | Equal-Weight |
| 10/28/2022 | 44.7% | Truist Securities | $140 → $130 | Maintains | Buy |
| 10/28/2022 | 61.4% | Oppenheimer | $175 → $145 | Maintains | Outperform |
| 10/27/2022 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 10/24/2022 | 83.66% | Deutsche Bank | $175 → $165 | Maintains | Buy |
| 10/05/2022 | 55.83% | Truist Securities | $150 → $140 | Maintains | Buy |
| 10/03/2022 | 50.27% | Benchmark | $165 → $135 | Maintains | Buy |
| 08/02/2022 | 5.74% | UBS | $145 → $95 | Downgrades | Neutral → Sell |
| 08/01/2022 | 55.83% | Raymond James | $180 → $140 | Maintains | Outperform |
| 07/29/2022 | 71.42% | Barclays | $181 → $154 | Maintains | Overweight |
| 07/28/2022 | 83.66% | Benchmark | $175 → $165 | Maintains | Buy |
| 07/14/2022 | 66.96% | Truist Securities | $175 → $150 | Maintains | Buy |
| 06/29/2022 | 42.48% | Stifel | → $128 | Initiates Coverage On | → Hold |
| 06/21/2022 | 13.54% | B of A Securities | $145 → $102 | Downgrades | Neutral → Underperform |
| 06/21/2022 | 94.79% | Deutsche Bank | $210 → $175 | Maintains | Buy |
| 06/21/2022 | 94.79% | Truist Securities | $200 → $175 | Maintains | Buy |
| 06/21/2022 | 39.14% | Stephens & Co. | $155 → $125 | Maintains | Equal-Weight |
| 06/21/2022 | 19.1% | SVB Leerink | $117 → $107 | Maintains | Market Perform |
| 05/27/2022 | 30.23% | SVB Leerink | $131 → $117 | Maintains | Market Perform |
| 04/29/2022 | 102.58% | Credit Suisse | $181 → $182 | Maintains | Outperform |
| 04/29/2022 | 100.36% | Raymond James | $200 → $180 | Maintains | Outperform |
| 04/29/2022 | 45.81% | SVB Leerink | $162 → $131 | Maintains | Market Perform |
| 03/01/2022 | 87% | UBS | $152 → $168 | Upgrades | Sell → Neutral |
| 02/25/2022 | 117.05% | Credit Suisse | $200 → $195 | Maintains | Outperform |
| 02/25/2022 | 122.62% | Oppenheimer | $225 → $200 | Maintains | Outperform |
| 02/25/2022 | 111.49% | BMO Capital | → $190 | Upgrades | Market Perform → Outperform |
| 02/24/2022 | 94.79% | Benchmark | $200 → $175 | Maintains | Buy |
| 02/18/2022 | 63.62% | SVB Leerink | $145 → $147 | Maintains | Market Perform |
| 12/21/2021 | 137.09% | Barclays | $236 → $213 | Maintains | Overweight |
| 11/08/2021 | 150.45% | Raymond James | $250 → $225 | Maintains | Outperform |
| 11/04/2021 | 128.18% | Credit Suisse | $192 → $205 | Maintains | Outperform |
| 11/04/2021 | 105.92% | Stephens & Co. | $178 → $185 | Maintains | Equal-Weight |
| 11/04/2021 | 145.99% | RBC Capital | $244 → $221 | Maintains | Outperform |
| 11/04/2021 | 101.47% | SVB Leerink | $170 → $181 | Maintains | Market Perform |
| 11/03/2021 | 150.45% | Oppenheimer | $265 → $225 | Maintains | Outperform |
| 10/13/2021 | 111.49% | Truist Securities | $255 → $190 | Maintains | Buy |
| 09/27/2021 | 89.23% | SVB Leerink | → $170 | Initiates Coverage On | → Market Perform |
| 09/24/2021 | 66.96% | UBS | → $150 | Initiates Coverage On | → Sell |
| 09/10/2021 | 117.05% | Cowen & Co. | → $195 | Initiates Coverage On | → Market Perform |
| 08/11/2021 | 178.27% | Credit Suisse | $330 → $250 | Maintains | Outperform |
| 08/10/2021 | 161.58% | Benchmark | $325 → $235 | Maintains | Buy |
| 08/10/2021 | 178.27% | Raymond James | $325 → $250 | Maintains | Outperform |
| 08/06/2021 | 194.97% | Oppenheimer | $325 → $265 | Maintains | Outperform |
| 08/06/2021 | 163.8% | Stephens & Co. | $310 → $237 | Maintains | Equal-Weight |
| 08/05/2021 | 144.88% | B of A Securities | → $220 | Downgrades | Buy → Neutral |
| 02/23/2021 | 261.75% | Benchmark | $275 → $325 | Maintains | Buy |
| 02/08/2021 | 278.45% | Deutsche Bank | $275 → $340 | Maintains | Buy |
| 10/30/2020 | 211.67% | Credit Suisse | $246 → $280 | Maintains | Outperform |
| 09/21/2020 | 189.4% | Oppenheimer | $250 → $260 | Maintains | Outperform |
| 09/02/2020 | 200.53% | BMO Capital | $250 → $270 | Maintains | Market Perform |
| 07/30/2020 | 200.53% | SunTrust Robinson Humphrey | $260 → $270 | Maintains | Buy |
| 07/30/2020 | 183.84% | Raymond James | $210 → $255 | Maintains | Outperform |
| 07/30/2020 | 189.4% | Deutsche Bank | $220 → $260 | Maintains | Buy |
| 07/30/2020 | 178.27% | Benchmark | $210 → $250 | Maintains | Buy |
| 07/30/2020 | 189.4% | RBC Capital | $218 → $260 | Maintains | Outperform |
| 07/29/2020 | 178.27% | Jefferies | $225 → $250 | Maintains | Buy |
| 07/10/2020 | 189.4% | SunTrust Robinson Humphrey | $240 → $260 | Maintains | Buy |
| 06/18/2020 | 133.75% | Benchmark | → $210 | Upgrades | Hold → Buy |
| 05/21/2020 | 167.14% | SunTrust Robinson Humphrey | $225 → $240 | Maintains | Buy |
| 05/11/2020 | 111.49% | UBS | $208 → $190 | Maintains | Neutral |
| 05/11/2020 | 133.75% | Raymond James | $225 → $210 | Maintains | Outperform |
| 03/09/2020 | 128.18% | Benchmark | → $205 | Upgrades | Hold → Buy |
| 02/21/2020 | 131.52% | UBS | $154 → $208 | Maintains | Neutral |
| 02/21/2020 | 122.62% | Stephens & Co. | $180 → $200 | Maintains | Equal-Weight |
| 02/20/2020 | 150.45% | SunTrust Robinson Humphrey | $185 → $225 | Maintains | Buy |
| 02/20/2020 | 150.45% | Raymond James | $200 → $225 | Maintains | Outperform |
| 01/17/2020 | 129.3% | Credit Suisse | → $206 | Initiates Coverage On | → Outperform |
| 01/03/2020 | 122.62% | Raymond James | $144 → $200 | Maintains | Outperform |
| 12/18/2019 | 105.92% | SunTrust Robinson Humphrey | $175 → $185 | Maintains | Buy |
| 12/06/2019 | 89.23% | BMO Capital | → $170 | Initiates Coverage On | → Market Perform |
| 11/26/2019 | 98.13% | B of A Securities | $170 → $178 | Maintains | Buy |
| 11/20/2019 | 89.23% | B of A Securities | $163 → $170 | Reiterates | → Buy |
| 11/07/2019 | 71.42% | UBS | $144 → $154 | Maintains | Neutral |
| 11/01/2019 | — | Baird | Upgrades | Neutral → Outperform | |
| 10/22/2019 | 61.4% | Stephens & Co. | → $145 | Reinstates | → Equal-Weight |
| 09/17/2019 | 72.53% | Deutsche Bank | → $155 | Initiates Coverage On | → Buy |
| 08/05/2019 | 39.14% | Barclays | $120 → $125 | Maintains | Equal-Weight |
| 07/15/2019 | 60.28% | Raymond James | $140 → $144 | Maintains | Outperform |
| 05/02/2019 | 55.83% | Raymond James | → $140 | Upgrades | Market Perform → Outperform |
| 03/21/2019 | 33.57% | Barclays | $115 → $120 | Maintains | Equal-Weight |
| 02/05/2019 | — | Benchmark | Downgrades | Buy → Hold | |
| 12/14/2018 | 44.7% | Barclays | → $130 | Initiates Coverage On | → Equal-Weight |
| 11/16/2018 | 40.25% | UBS | → $126 | Initiates Coverage On | → Neutral |
| 10/30/2018 | — | Benchmark | Upgrades | Hold → Buy | |
| 10/26/2018 | 15.76% | Craig-Hallum | $116 → $104 | Downgrades | Buy → Hold |
| 10/11/2018 | 33.57% | Baird | $105 → $120 | Maintains | Neutral |
| 10/11/2018 | 39.14% | Cantor Fitzgerald | $117 → $125 | Maintains | Neutral |
| 09/18/2018 | 54.72% | B of A Securities | $116 → $139 | Maintains | Buy |
| 09/13/2018 | 30.23% | Cantor Fitzgerald | → $117 | Initiates Coverage On | → Neutral |
What is the target price for Amedisys (AMED)?
The latest price target for Amedisys (NASDAQ: AMED) was reported by Credit Suisse on July 27, 2023. The analyst firm set a price target for $101.00 expecting AMED to rise to within 12 months (a possible 12.42% upside). 43 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Amedisys (AMED)?
The latest analyst rating for Amedisys (NASDAQ: AMED) was provided by Credit Suisse, and Amedisys reiterated their neutral rating.
When is the next analyst rating going to be posted or updated for Amedisys (AMED)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amedisys, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amedisys was filed on July 27, 2023 so you should expect the next rating to be made available sometime around July 27, 2024.
Is the Analyst Rating Amedisys (AMED) correct?
While ratings are subjective and will change, the latest Amedisys (AMED) rating was a reiterated with a price target of $0.00 to $101.00. The current price Amedisys (AMED) is trading at is $89.84, which is within the analyst's predicted range.